91370-63-7

Upstream product

• 10236-14-3 4-(diethoxyphosphoryl)-but-2-enoic acid ethyl ester 
• 141359-47-9 C₁₈H₂₃NO₂ 
• 142247-37-8 4-(3-ethoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 316362-81-9 ethyl trans-4-(N-benzyl-4'-piperidinyliden)-2-butenoate 
• 25370-46-1 ethyl 4-(pyridin-4-yl)-4-oxobutanoate 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 1334106-46-5 1-benzyl-4-(4-chlorobutyl)piperidine 
• 1334106-35-2 N-{[5-(4-(1-benzylpiperidin-4-yl)butoxy)-1-methyl-1H-indol-2-yl]methyl}-N-methylprop-2-yn-1-amine 
• 316362-85-3 ethyl 4-(N-benzyl-4'-piperidinyl)-2-butanoate 
• 99198-79-5 4-(3-ethoxycarbonylpropyl)piperidine-1-carboxylic acid benzyl ester 
• 315719-45-0 5-{4-[4-(diethylamino)butyl]-1-piperidinyl}acetyl-5H-dibenz[b,f]azepine 
• 316363-34-5 4-[4-(N-benzoyl-N-methylamino)butyl]-N-benzylpiperidine 
• 316362-90-0 methanesulfonic acid 4-(1-benzyl-piperidin-4-yl)-butyl ester 
• 316362-88-6 4-[4-(diethylamino)butyl]-N-benzylpiperidine 
• 316363-35-6 4-[4-(N-benzoyl-N-methylamino)butyl]piperidine 
• 316363-16-3 benzyl-methyl-(4-piperidin-4-yl-butyl)-amine 
• 316363-33-4 4-[4-(methylamino)butyl]-N-benzylpiperidine 
• 318508-02-0 4-(N-benzyl-4'-piperidinyl)-1-butanol 
• 374776-42-8 4-(5-(4-(3-ethoxycarbonylpropyl)piperidinylsulfonyl)-2-n-propoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide 
• 374776-41-7 4-(2-ethoxy-5-(4-(3-ethoxycarbonylpropyl)piperidinylsulfonyl)benzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide 

Relevant academic research and scientific papers

Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease

A new family of multitarget molecules able to interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as with monoamino oxidase (MAO) A and B, has been synthesized. Novel compounds (3-9) have been designed using a conjunctive approach that combines the benzylpiperidine moiety of the AChE inhibitor donepezil (1) and the indolyl propargylamino moiety of the MAO inhibitor N-[(5-benzyloxy-1-methyl-1H-indol-2- yl)methyl]-N-methylprop-2-yn-1-amine (2), connected through an oligomethylene linker. The most promising hybrid (5) is a potent inhibitor of both MAO-A (IC50 = 5.2 ± 1.1 nM) and MAO-B (IC50 = 43 ± 8.0 nM) and is a moderately potent inhibitor of AChE (IC50 = 0.35 ± 0.01 μM) and BuChE (IC50 = 0.46 ± 0.06 μM). Moreover, molecular modeling and kinetic studies support the dual binding site to AChE, which explains the inhibitory effect exerted on Aβ aggregation. Overall, the results suggest that the new compounds are promising multitarget drug candidates with potential impact for Alzheimer's disease therapy. (Figure presented)

AZAARENE DERIVATIVES

A compound represented by the general formula: wherein X1 represents a nitrogen atom or a group represented by the formula -CR10=; X2 represents a nitrogen atom or a group represented by the formula -CR11=; Y represents an oxygen atom or the like; R1 represents a C1-6 alkoxy group, an optionally substituted C6-10 aryloxy group, a group represented by the formula -NR12aR12b or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like; R3, R4, R5, R6, R7, R8, R10 and R11 each independently represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or the like; R9 represents a group represented by the formula -NR16aR16b or the like; and R12a, R12b, R16a and R16b each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, a salt thereof, or a hydrate of the foregoing.

Synthesis of new cardioselective M2 muscarinic receptor antagonists

A series of 5H-dibenz[b,f]azepine derivatives was prepared and evaluated for binding affinities to muscarinic receptors in vitro. Among them, compound 8 showed a high affinity for human recombinant M2 receptors (K(i)=2.6 nM), a low affinity for M4 receptors (39-fold less than for M2 receptors) and a very low affinity for M1 and M3 receptors (119- and 112-fold less than for M2 receptors, respectively). The high M2 selectivity of 8 may be attributed to the olefinic bond of the azepine ring. Functional experiments showed 8 to be a competitive antagonist with high affinity to the cardiac (pA2=7.1) and low affinity to the intestinal muscarinic receptors (IC50=0.54 μM). In vivo experiments confirmed the in vitro M2 selectivity of 8. Acetylcholine-induced bradycardia was dose-dependently antagonized in rats after both intravenous and intraduodenal administration of 8. In rats, cholinergic functions mediated by M1 or M3 receptors (salivary secretion, pupil diameter, gastric emptying, intestinal transit time) were not affected by the oral administration of 8 even at doses as high as 30 times the antibradycardic effective dose. Furthermore, 8 had no analgesic activity in mice, indicating poor central nervous system penetration. In dogs, nocturnal bradycardia was dose-dependently inhibited by the oral route with a duration of action of about 24h. Compound 8 appears to be a promising cardioselective antimuscarinic agent for the treatment of dysfunctions of the cardiac conduction system such as sinus or nodal bradycardia ('sick-sinus syndrome') and atrioventricular block.

(Benzhydryloxyethylpiperidyl) aliphatic acid derivatives and their use in the treatment of allergies and asthma

Compounds of formula (I): STR1 in which: R1 and R2 are independently alkyl, alkoxy, trifluoromethyl, nitro or halogen; A is an aliphatic hydrocarbon group having from 2 to 8 carbon atoms whose chain contains at least 2 carbon atoms i

Condensed seven-membered ring compounds, their production and use

Novel condensed seven-membered ring compounds of the formula: STR1 [wherein R1 and R2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R3 and R5 are independently hydrogen, lower alkyl or aralkyl; R4 is hydrogen or lower alkyl; R6 is a condensed or non-condensed hetero-alicyclic containing at least one atom of N, O and S as a ring-forming atom which may be substituted; A is an alkylene chain; n is 1 or 2] and salts thereof. These compounds exhibit inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases, such as hypertension, cardiopathy and cerebral apoploxy.

3-Amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives

Novel 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives of the formula STR1 [wherein R1 and R2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R3 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl; R4 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted cycloalkylalkyl; Y is a carboxyl group which may be esterified or amidated; m is 1 or 2] and salts thereof. These compounds and salts thereof exhibits inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases (e.g. hypertension, cardiopathy, cerebral apoploxy).